Premium
Assessment of the use of sialogogues in the clinical management of patients with xerostomia
Author(s) -
ChainaniWu Nita,
Gorsky Meir,
Mayer Priscilla,
Bostrom Alan,
Epstein Joel B.,
Jr. Sol Silverman
Publication year - 2006
Publication title -
special care in dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.328
H-Index - 41
eISSN - 1754-4505
pISSN - 0275-1879
DOI - 10.1111/j.1754-4505.2006.tb01719.x
Subject(s) - bethanechol , medicine , pilocarpine , saliva , crossover study , adverse effect , washout , anesthesia , side effect (computer science) , placebo , muscarinic acetylcholine receptor , receptor , alternative medicine , pathology , psychiatry , computer science , epilepsy , programming language
This study was conducted to assess the clinical efficacy and adverse effects of pilocarpine, bethanechol and cevimeline In patients with xerostomia. In this open‐label crossover assessment in 20 patients with xerostomia, a one‐ to two‐week course of each medication with a one‐week washout period was prescribed. Side effects, symptoms, whole stimulated and unstimulated saliva were measured. Each sialogogue was found to increase saliva and decrease symptoms. A mixed‐effects analysis showed a greater increase in stimulated saliva on bethanechol compared to pilocarpine (0.106, p=0.0272). Increased sweating was the most common side effect, experienced more frequently with pilocarpine as compared to bethanechol (p=0.0588) or cevimeline (p= 0.0143). A carryover effect beyond the washout period was seen. Effects on saliva and side effects vary between sialogogues, suggesting a benefit of trials with different sialogogues to determine individual patient preference. The observed carryover effect suggests that intermittent treatment may be an alternative to continuous treatment with sialogogues.